Frankel Arthur E, Flaherty Keith T, Weiner George J, Chen Robert, Azad Nilofer S, Pishvaian Michael J, Thompson John A, Taylor Matthew H, Mahadevan Daruka, Lockhart A Craig, Vaishampayan Ulka N, Berlin Jordan D, Smith David C, Sarantopoulos John, Riese Matthew, Saleh Mansoor N, Ahn Chul, Frenkel Eugene P
University of Texas Southwestern Medical Center, Dallas, Texas, USA
Harvard Medical School, Boston, Massachusetts, USA.
Oncologist. 2017 Apr;22(4):369-374. doi: 10.1634/theoncologist.2016-0409. Epub 2017 Mar 17.
Multiple factors critical to the effectiveness of academic phase I cancer programs were assessed among 16 academic centers in the U.S. Successful cancer centers were defined as having broad phase I and I/II clinical trial portfolios, multiple investigator-initiated studies, and correlative science. The most significant elements were institutional philanthropic support, experienced clinical research managers, robust institutional basic research, institutional administrative efforts to reduce bureaucratic regulatory delays, phase I navigators to inform patients and physicians of new studies, and a large cancer center patient base. New programs may benefit from a separate stand-alone operation, but mature phase I programs work well when many of the activities are transferred to disease-oriented teams. The metrics may be useful as a rubric for new and established academic phase I programs. 2017;22:369-374.
在美国的16个学术中心对多项影响学术性I期癌症项目有效性的关键因素进行了评估。成功的癌症中心被定义为拥有广泛的I期和I/II期临床试验组合、多项研究者发起的研究以及相关科学研究。最重要的因素包括机构慈善支持、经验丰富的临床研究管理人员、强大的机构基础研究、机构为减少官僚监管延误所做的行政努力、为患者和医生提供新研究信息的I期导航员以及庞大的癌症中心患者群体。新的项目可能会从单独的独立运营中受益,但成熟的I期项目在许多活动转移到以疾病为导向的团队时运行良好。这些指标可能作为新的和已有的学术性I期项目的评判标准。2017年;22:369 - 374。